Radiation Therapy and Nivolumab with Relatlimab-rmbw Achieved a Complete Response in Metastatic Cutaneous Melanoma to the Orbit

Ophthalmic Plastic and Reconstructive Surgery 2026

View at publisher
Authors: Brandon T. Sellers, Amina Lateef Chaudhry, Devarati Mitra, Kim O. Learned, Oded Sagiv
DOI: 10.1097/iop.0000000000003162
Cited by: 0
References: 9

Abstract

We present a patient with left orbital metastasis of cutaneous melanoma, treated with 30 Gy in 10 fraction radiation therapy followed by a combination of programmed death-1 inhibitor, nivolumab, and lymphocyte-activation gene inhibitor, relatlimab. The patient achieved a complete response to treatment, with no evidence of recurrence of the orbital mass, 17 months after treatment initiation.

Fields of Study & Subjects

Ocular Oncology and Treatments Cancer Immunotherapy and Biomarkers Cutaneous Melanoma Detection and Management

Publication details

Journal / source
Ophthalmic Plastic and Reconstructive Surgery
Volume
42
Issue
5
Pages
e215–e219
Publication date
12 January 2026
Language
EN